[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352619-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352619-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tumor-immune-spatiotemporal-co-evolution-as-a-paradigm-for-overcoming-therapy-resistance-in-advanced-prostate-cancer","Tumor-immune spatiotemporal co-evolution as a paradigm for overcoming therapy resistance in advanced prostate cancer","","Reviewing metastatic castration-resistant prostate cancer (mCRPC), the article argues that therapeutic resistance is shaped by dynamic tumor microenvironment (TME) reprogramming in addition to tumor-intrinsic genomic changes. It presents an ecosystem-level tumor-immune spatiotemporal co-evolution framework spanning temporal disease stages and spatial niche architecture. Clinical and multiomics data are synthesized into a probabilistic trajectory from immune-permissive states to terminal immune-desert phenotypes. Using OCEBM 2011 criteria, mechanistic claims are graded and five core, evidence-ranked conclusions are proposed.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tumor-immune-spatiotemporal-co-evolution-as-a-paradigm-for-overcoming-therapy-resistance-in-advanced-prostate-cancer/352619/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tumor-immune-spatiotemporal-co-evolution-as-a-paradigm-for-overcoming-therapy-resistance-in-advanced-prostate-cancer/352619.png","ImageObject",300,407,{"name":42,"@type":43},"Jake","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the review propose as the paradigm for therapy resistance in advanced prostate cancer?","Question",{"text":63,"@type":64},"It proposes a tumor-immune spatiotemporal co-evolution paradigm that reframes mCRPC resistance as ecosystem-level adaptation across temporal disease stages and spatial niche architecture.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the article evaluate the strength of mechanistic claims?",{"text":68,"@type":64},"It systematically applies the OCEBM 2011 criteria, grading evidence to distinguish peer-reviewed validated findings (Level 1–2b) from speculative hypotheses (Level 3–4).",{"name":70,"@type":61,"acceptedAnswer":71},"What role do cancer-associated fibroblasts (CAFs) play in immunosuppression according to the review?",{"text":72,"@type":64},"The review delineates how spatially organized CAF subsets architect immunosuppressive niches and contribute through subset heterogeneity and reciprocal metabolic symbiosis with tumor cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352619,1790334359,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 11 March 2026  \nDOI 10.3389/fimmu.2026.1797299  \nOPEN ACCESS  \nEDITED BY  \nChenshen Huang,  \nFuzhou University, China  \nREVIEWED BY  \nAli Amiryouseﬁ,  \nHarvard University, United States Danial Hashemi Karoii, University of Tehran, Iran  \n*CORRESPONDENCE  \nMeng Zhang  \n [zh3028@zuaa.zju.edu.cn](zh3028@zuaa.zju.edu.cn)  \nRECEIVED 27 January 2026  \nREVISED 23 February 2026  \nACCEPTED 25 February 2026  \nPUBLISHED 11 March 2026  \nCITATION  \nXue J, Liao K and Zhang M (2026) Tumor-immune spatiotemporal co-evolution as a paradigm for overcoming therapy resistance in advanced prostate cancer.  \nFront. Immunol. 17:1797299 .  \ndoi: 10.3389/fimmu.2026.1797299  \nCOPYRIGHT  \n© 2026 Xue, Liao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTumor-immune spatiotemporal co-evolution as a paradigm for overcoming therapy resistance in advanced prostate cancer  \nJunchao Xue, Kaisen Liao and Meng Zhang* Tongde Hospital of Zhejiang Province, Hangzhou, China  \nTherapeutic resistance in metastatic castration-resistant prostate cancer (mCRPC) is orchestrated not only by tumor-intrinsic genomic alterations but also by dynamic reprogramming of the tumor microenvironment (TME) . This review introduces the tumor-immune spatiotemporal co-evolution paradigm, which reframes mCRPC resistance as an ecosystem-level adaptation unfolding across temporal (disease stage) and spatial (niche architecture) dimensions. We synthesize clinical and multiomics data to map a probabilistic evolutionary trajectory from an immunepermissive state, through suppressive niche consolidation, to a terminal immune desert phenotype. In this review, we systematically apply the Oxford Centre for Evidence-Based Medicine (OCEBM) 2011 criteria to this ﬁeld, grading all mechanistic claims to explicitly distinguish peer-reviewed, validated ﬁndings (Level 1–2b) from speculative hypotheses (Level 3–4), and delineate 5 evidence-graded core conclusions of the tumor-immune co-evolution paradigm. We delineate how spatially organized cancer-associated ﬁbroblast (CAF) subsets architect immunosuppressive niches and engage in reciprocal metabolic symbiosis with tumor cells, and redeﬁne therapeutics as dominant selective pressures that drive clonal-stromal co-selection to explain cross-resistance across treatment modalities. To translate this paradigm, we propose an integrative closed-loop “Dynamic Monitoring—Mechanistic Parsing—Synergistic Intervention ” framework, with concrete, clinically actionable strategies grounded in 2024–2025 peer-reviewed prostate cancer research. This framework advocates for longitudinal ecological auditing of the TME to rationally guide mechanistically orthogonal combination therapies. Our objective is to provide a rigorously evidence-based roadmap for transforming mCRPC into a chronically manageable condition through precision ecological intervention, offering a novel, actionable perspective to advance prostate cancer immunotherapy and overcome immune evasion for researchers and clinicians in the ﬁeld of cancer immunology.  \nKEYWORDS  \ncancer-associated ﬁbroblasts, clonal-stromal co-selection, immune checkpoint blockade, prostate cancer immunotherapy, radiopharmaceutical therapy, spatiotemporal co-evolution, therapy resistance, tumor microenvironment  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nHighlights  \n• The prostate tumor–immune ecosystem undergoes predictable spatiotemporal co-evolution across disease stages, with paired patient specimen analyses conﬁrming progressive immune suppression from hormone-sensitive prosta","cbCaifqW94vcAcEy","https://ap.wps.com/l/cbCaifqW94vcAcEy","pdf",7191367,16,"English","# Highlights\n## Spatiotemporal co-evolution and immune suppression across disease stages\n## Mechanistic roles of cancer-associated fibroblast subsets and metabolism\n## Therapeutics as dominant selective pressures driving cross-resistance\n## Closed-loop dynamic monitoring framework for precision intervention\n## Need for prospective longitudinal ecological auditing trials\n# 1 Introduction: the imperative for an ecosystem-centric perspective\n## From localized prostate cancer to mCRPC and NEPC as therapeutic adaptation\n## Limitations of a purely tumor-intrinsic genomic lens","[{\"question\":\"What does the review propose as the paradigm for therapy resistance in advanced prostate cancer?\",\"answer\":\"It proposes a tumor-immune spatiotemporal co-evolution paradigm that reframes mCRPC resistance as ecosystem-level adaptation across temporal disease stages and spatial niche architecture.\"},{\"question\":\"How does the article evaluate the strength of mechanistic claims?\",\"answer\":\"It systematically applies the OCEBM 2011 criteria, grading evidence to distinguish peer-reviewed validated findings (Level 1–2b) from speculative hypotheses (Level 3–4).\"},{\"question\":\"What role do cancer-associated fibroblasts (CAFs) play in immunosuppression according to the review?\",\"answer\":\"The review delineates how spatially organized CAF subsets architect immunosuppressive niches and contribute through subset heterogeneity and reciprocal metabolic symbiosis with tumor cells.\"}]","Tumor-immune spatiotemporal co-evolution as a paradigm for overcoming therapy resistance in advanced prostate cancer | PDF",1790100504,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e32edffb57264ee81533d48592b7693d.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f8c9f80f6ab45becc927fe1c8bdd80d.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9852943e3af3cb6cb8be5519ccdb5785.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e073ba7d9fa30e871e17257b8924fbac.webp",980,1385]